Guardant Health (GH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.67 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 15.79%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.72 per share when it actually produced a loss of $0.46, delivering a surprise of 36.11%. Over the last four quart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specifi ...

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance Revenue growth of 29% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield approved by FDA as primary option for CRC screening and is commercially available in U.S. PALO ALTO, Calif. August 7, 2024 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlight ...

Wall Street analysts forecast that Guardant Health (GH) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial p ...

Shield is the first blood test that the FDA has approved as a primary screening option for colorectal cancer and the first that meets Medicare coverage performance requirements, the company said. The test is for adults age 45 and older who carry an average risk. FDA Approval Is 'Significant Victory' In a study, the Shield test showed 83% sensitivity in detecting colorectal cancer, including 90% specificity for advanced neoplasia, the company said. tips@investopedia.com Guardant Health's Shield blood test fo ...

On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease. The company says it is the first blood test approved by the FDA as a primary screening option for CRC, meaning healthcare providers can offer Shield like all other non-invasive methods recommended in screening guidelines. Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly trea ...

signal a downward trend. After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving ave ...

After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common movin ...

Group 1 - Guardant Health (GH) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - GH has moved 47.1% higher over the last four weeks, suggesting potential for another rally [2] - The company has a Zacks Rank 3 (Hold) and has seen positive earnings estimate revisions, with 5 higher estimates compared to none lower for the current fiscal year [2] Group 2 - Investors are encouraged to consider adding GH to their watchlist due to the important technical indicator and positive earnings estimate revisions [3]

Guardant Health (GH) stock rocketed Friday after a Food and Drug Administration panel recommended the agency approve Guardant's blood-based colon cancer screening test. X The FDA's Medical Devices Advisory Committee voted eight to one that Guardant's blood-based test, known as Shield, is safe. Six out of nine panelists said the test appears effective, and seven to two voted that the benefits outweigh the risks. If approved, Guardant's blood-based test would rival Exact Sciences' (EXAS) Cologuard, an already ...